AR025929A1 - Compuestos para el tratamiento de enfermedades mediadas por virus - Google Patents

Compuestos para el tratamiento de enfermedades mediadas por virus

Info

Publication number
AR025929A1
AR025929A1 ARP000105177A ARP000105177A AR025929A1 AR 025929 A1 AR025929 A1 AR 025929A1 AR P000105177 A ARP000105177 A AR P000105177A AR P000105177 A ARP000105177 A AR P000105177A AR 025929 A1 AR025929 A1 AR 025929A1
Authority
AR
Argentina
Prior art keywords
interferon
mediumed
virus
diseases
compounds
Prior art date
Application number
ARP000105177A
Other languages
English (en)
Original Assignee
Inst Of Molecul & Cell Biology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Of Molecul & Cell Biology filed Critical Inst Of Molecul & Cell Biology
Publication of AR025929A1 publication Critical patent/AR025929A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C07D215/52—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4 with aryl radicals attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Las infecciones de Flavivirus, Rhabdovirus y Paramixovirus pueden tratarse mediante la administracion de un inhibidor de la enzima dihidroorotatodehidrogenasa tal como la sal de sodio de ácido6-fluoro-2-(2-flouro-1,1-bifenil-4-ilo)-3-metil-4-quinoli nacarboxílico (Brequinar). Un efecto sinergísticopuede obtenerse si también se administra una interferona tal como la interferona a2, interferona a8 o interferona Beta, o un inhibidor de unasegunda enzimaseleccionada desde inosina monofosfato dehidr ogenasa, guanosina monofosfato sintetasa, histidina trifosfato sintetasa y S-adenosilhomocisteína hidrolasa.
ARP000105177A 1999-10-01 2000-09-29 Compuestos para el tratamiento de enfermedades mediadas por virus AR025929A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15701799P 1999-10-01 1999-10-01

Publications (1)

Publication Number Publication Date
AR025929A1 true AR025929A1 (es) 2002-12-18

Family

ID=22562034

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000105177A AR025929A1 (es) 1999-10-01 2000-09-29 Compuestos para el tratamiento de enfermedades mediadas por virus

Country Status (5)

Country Link
EP (1) EP1237546A2 (es)
JP (1) JP2003510352A (es)
AR (1) AR025929A1 (es)
AU (1) AU7622000A (es)
WO (1) WO2001024785A2 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7365094B2 (en) 2002-12-23 2008-04-29 4Sc Ag Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
EP1581477B1 (en) 2002-12-23 2009-12-02 4Sc Ag Cycloalkene dicarboxylic acid compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
US7071355B2 (en) 2002-12-23 2006-07-04 4 Sc Ag Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
US7247736B2 (en) 2002-12-23 2007-07-24 4Sc Ag Method of identifying inhibitors of DHODH
CL2004000985A1 (es) 2003-05-16 2005-01-14 Wyeth Corp Compuestos derivados de fenilquinolinas; composicion farmaceutica, proceso de preparacion; y uso para tratar osteoporosis, enfermedad de paget, dano vascular, osteoartritis, cancer oseo, cancer ovarico, cancer prostatico, hipercolesterolemia, aterosc
JP2006526022A (ja) * 2003-05-23 2006-11-16 ペスカ バイオメディカル ラボラトリーズ， インク． 重症急性呼吸器症候群及び他のウィルス感染の治療のためのインターフェロンの使用
AU2005282554A1 (en) 2004-09-07 2006-03-16 Wyeth 6H-[1]benzopyrano[4,3-b]quinolines and their use as estrogenic agents
US20100068147A1 (en) * 2006-10-05 2010-03-18 Agency for Science , Technology and Research Dengue diagnosis and treatment
WO2009016812A1 (ja) * 2007-07-27 2009-02-05 Kowa Company, Ltd. ２－フェニルキノリン－４－カルボン酸誘導体を有効成分とする貧血の予防及び／又は治療剤
TWI530286B (zh) * 2009-05-04 2016-04-21 帕納特斯製藥格斯有限公司 作為抑制病毒化合物之抗發炎劑
US8710079B2 (en) 2010-04-23 2014-04-29 National Health Research Institutes Quinoline compounds and their use for treating viral infection
US8686048B2 (en) 2010-05-06 2014-04-01 Rhizen Pharmaceuticals Sa Immunomodulator and anti-inflammatory compounds
US20140031383A1 (en) 2011-02-08 2014-01-30 Dana-Farber Cancer Institute, Inc. Methods for treatment of melanoma
US9663488B2 (en) * 2013-01-28 2017-05-30 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
US11028054B2 (en) * 2017-02-24 2021-06-08 Merck Patent Gmbh 1, 4, 6-trisubstituted-2-alkyl-1H-benzo[d]imidazole derivatives as dihydroorotate oxygenase inhibitors
KR20210048483A (ko) * 2018-06-22 2021-05-03 오하이오 스테이트 이노베이션 파운데이션 디하이드로오로테이트 데하이드로게나제의 억제 방법 및 조성물
CN109864989B (zh) * 2019-03-08 2021-07-23 中国农业科学院兰州兽医研究所 一种布喹那在制备预防***病毒感染的药物中的应用
CN113874375A (zh) * 2019-06-03 2021-12-31 株式会社大分大学先端医学研究所 用于治疗狂犬病的环状酰胺化合物及其方法
IT202000027251A1 (it) * 2020-11-13 2022-05-13 Donatella Boschi Inibitori della diidroorotato deidrogenasi umana (hdhodh) per l'uso come antivirali
WO2024092210A1 (en) * 2022-10-27 2024-05-02 University Of Virginia Patent Foundation Targeting the m6a mrna demethylase fto

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4680299A (en) * 1984-04-30 1987-07-14 E.I. Du Pont De Nemours And Company 2-phenyl-4-quinolinecarboxylic acids and pharmaceutical compositions thereof
DK0601191T3 (da) * 1992-04-24 1999-04-26 Kyowa Hakko Kogyo Kk Hidtil ukendt tetracyklisk forbindelse
WO1995009153A1 (fr) * 1993-09-28 1995-04-06 Kyowa Hakko Kogyo Co., Ltd. Nouveau compose tetracyclique
JPH10231289A (ja) * 1996-12-06 1998-09-02 Kyowa Hakko Kogyo Co Ltd 四環系キノリン誘導体

Also Published As

Publication number Publication date
WO2001024785A2 (en) 2001-04-12
EP1237546A2 (en) 2002-09-11
WO2001024785A3 (en) 2002-07-11
JP2003510352A (ja) 2003-03-18
AU7622000A (en) 2001-05-10

Similar Documents

Publication Publication Date Title
AR025929A1 (es) Compuestos para el tratamiento de enfermedades mediadas por virus
TW200633995A (en) Andrographolide derivatives to treat viral infections
ATE541844T1 (de) Antivirale verbindungen
BRPI0415883A (pt) compostos e composições de nucleosìdeo para o tratamento de infecções virais
BRPI0514425A (pt) inibidores de rna polimerase dependente de rna do vìrus da hepatite c, e composições e tratamentos usando os mesmos
ATE475660T1 (de) Antivirale verbindungen
BR0206614A (pt) Composto, composição farmacêutica, método para inibir a polimerase viral de rna dependente de rna e/ou inibir a replicação viral de rna dependente de rna, método para tratar uma infecção viral de rna dependente de rna, e, uso de um composto
AR034448A1 (es) Uso de derivados de nucleosidos, dichos derivados de nucleosidos para dicho uso, composiciones farmaceuticas que los comprenden y uso de dichas composiciones
EA200500584A1 (ru) Нуклеозидные производные для лечения инфекционных заболеваний, вызванных вирусом гепатита c
BRPI0516825A (pt) inibição da protease ns3-ns4a do vìrus da hepatite c (vhc)
ATE478886T1 (de) Purin nucleoside für die behandlung von durch flavividrae verursachten krankheiten, einschliesslich hepatitis c
BR0309581A (pt) Derivados de nucleosìdeo para tratamento de infecção por vìrus de hepatite c
BR0305259A (pt) Inibidores de hcv ns5b polimerase
PE20000949A1 (es) Tripeptidos inhibidores de la hepatitis c
PA8588501A1 (es) Derivados antivirales de nucleósidos
CL2004001161A1 (es) Compuestos describe compuestos derivados de quinolina; composicion farmaceutica; y su uso para tratar una enfermedad causada por el virus de la hepatitis c.
UY28423A1 (es) Inhibidores de proteasas serinas, en especial proteasa ns3-ns4a del vhc.-
BRPI0517463A (pt) inibidores da protease do vìrus da hepatite c, composições e tratamentos usando os mesmos
NO20065736L (no) Substituerte arylacyltioureaer og relaterte forbindelser; Inhibitorer av viral reproduksjon
WO2003105770A3 (en) CARBOCYCLIC NUCLEOSIDE DERIVATIVES FOR USE AS VIRAL RNA-DEPENDENT RNA POLYMERASE INHIBITORS
EA200800178A1 (ru) Ингибиторы вируса гепатита с (hcv)
CR20220675A (es) Análogos de nucleósido de 1´- ciano y usos de los mismos
BR0316397A (pt) Tiouréias aril substituìdas e compostos relacionados como inibidores de replicação viral
EA200600227A1 (ru) Замещённые арилтиомочевины, применимые в качестве ингибиторов репликации вирусов
DK1077718T3 (da) Forøgelse af aktiviteten af antibakterielle oxazolidinon-midler ved anvendelse af argininderivater